Shanghai Shen Lian Biomedical Corporation Class A

As of June 30, 2026, Shanghai Shen Lian Biomedical Corporation Class A carries a market capitalization of 3.53B, placing it among publicly traded companies globally. Its enterprise value stands at 3.52B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Shanghai Shen Lian Biomedical Corporation Class A has 410.64M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 17.06, and the price-to-book ratio stands at 2.54.

These figures are as of June 30, 2026. The EV/Sales ratio of 17.15 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 3.52B versus a market cap of 3.53B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Shanghai Shen Lian Biomedical Corporation Class A maintains a current ratio of 3.54, meaning it holds 3.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 3.83, indicating elevated leverage, while an interest coverage ratio of -95.42 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Shanghai Shen Lian Biomedical Corporation Class A posted a negative return on equity (ROE) of -3.56, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -3.20, reflecting losses generated across the asset base. The company generates approximately 542,154.21 in revenue per employee across its workforce of 379.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.89 indicates how many times Shanghai Shen Lian Biomedical Corporation Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Shanghai Shen Lian Biomedical Corporation Class A recorded an income tax benefit of -7.72M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -61.01M and -49.77M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Shanghai Shen Lian Biomedical Corporation Class A's stock has declined approximately 32.11% over the past 52 weeks. The 50-day moving average sits at 8.28, while the 200-day moving average is 8.74.

Over the twelve months ended June 30, 2026, Shanghai Shen Lian Biomedical Corporation Class A generated 205.48M in revenue and converted that into -49.77M in net income, yielding earnings per share of -0.13. EBITDA reached -61.41M, while operating income came in at -46.74M.

As of June 30, 2026, Shanghai Shen Lian Biomedical Corporation Class A holds 65.59M in cash and equivalents against 53.45M in total debt, resulting in a net debt position of -12.52M. Total book value stands at 1.39B, with working capital of 364.49M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Shanghai Shen Lian Biomedical Corporation Class A posted a gross margin of 54.40, reflecting its pricing power and cost economics. The operating margin of -22.75 and net profit margin of -24.22 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Shanghai Shen Lian Biomedical Corporation Class A paid dividends of 0.00 per share. The dividend payout ratio of -0.60 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -1.52, meaning Shanghai Shen Lian Biomedical Corporation Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Shanghai Shen Lian Biomedical Corporation Class A has an Altman Z-Score of 14.60, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.